Company intelligence / Profile preview

DermaXon

Missoula, Montana, United Statesdermaxon.com ↗

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

DermaXon's lead product DX308 is in pre-clinical development. The company has developed a treatment for acne that was nearly ready for clinical trials as of 2017.

Therapeutic areas: DermatologyNeurology
Modalities: Small moleculesProteolysis targeting chimera (PROTAC)
Industry: Biotech

Drug pipeline

7 assets

DX-465

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

Rodan + Fields (for Proactiv Solution treatment)

Beyond the preview

Go deeper on DermaXon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DermaXon.

Explore the full profile